Resources>Blog>Boost Your Drug Pipeline with Cost-Effective Human Antibody Solutions

Boost Your Drug Pipeline with Cost-Effective Human Antibody Solutions

Biointron 2024-12-04 Read time: 2 mins

pic.png

Fully human antibodies, developed using human genes, are advancing antibody-based therapeutics. These antibodies reduce immunogenicity, improving patient safety and tolerance. Traditional methods, like humanized mice, require genetic modifications to produce human antibodies, often increasing complexity and cost.

The collaboration between Biointron and Cyagen addresses these challenges with a next-generation platform. By combining Biointron's AbDrop™ technology and Cyagen's HUGO-Ab™ mice, researchers can discover fully human antibodies faster and at a lower cost. This platform accelerates timelines, reduces expenses, and delivers safer and more effective antibody candidates.

Key Advantages of the Biointron and Cyagen Platform

1. Faster Results

The platform significantly reduces timelines by eliminating the humanization process. Fully human antibodies can be identified within three months. This rapid turnaround is critical for biopharmaceutical companies aiming to bring therapies to market quickly.

2. Enhanced Accuracy and Diversity

Access to a diverse pool of high-affinity and highly specific antibodies ensures optimal targeting for therapeutic applications. The platform's precision reduces the risk of off-target effects, improving drug efficacy and safety.

3. Cost-Effectiveness

By streamlining the discovery process and leveraging cutting-edge technologies, the platform minimizes development costs.

4. Clear Intellectual Property (IP) and Royalty-Free Structure

A straightforward IP framework ensures smooth licensing and development processes, removing potential legal hurdles associated with patent disputes. 

Our High-throughput Fully Human Antibody Discovery Platform integrates Cyagen’s HUGO-Ab™ mice with Biointron’s AbDrop™ microdroplet-based single B cell screening. This powerful combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months. Learn more about the service here.

Subscribe to our Blog
Recommended Articles
Antibody-Drug Conjugates: An Advancing Field

As of the end of 2025, 21 ADCs have been approved globally, with four new approv……

Dec 26, 2025
Therapeutic Antibodies at the Intersection of Immune Tolerance and Tumor Immunity: Targeting Dendritic Cells, Tregs, and the Microenvironment
Dec 22, 2025
AET US 2025 – San Diego: Highlights and Event Recap

The 2025 Antibody Engineering & Therapeutics US (AET US) conference was held in ……

Dec 19, 2025
2025 mAbTalk Symposium – San Diego: Highlights and Event Recap

The 2025 mAbTalk Symposium by The Chinese Antibody Society was held in San Deigo……

Dec 17, 2025

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.